SOST and sclerosteosis: Rare monogenic disorders such as osteogenesis imperfecta, juvenile Paget disease, and sclerosteosis have illuminated critical bone regulatory pathways—indeed, the therapeutic target for romosozumab was identified through study of sclerosteosis patients lacking functional sclerostin [16].